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Background: There is evidence that calcium (Ca2+) increases the proliferation of human advanced prostate cancer
(PCa) cells but the ion channels involved are not fully understood. Here, we investigated the correlation between
alpha1D-adrenergic receptor (alpha1D-AR) and the transient receptor potential vanilloid type 1 (TRPV1) expression
levels in human PCa tissues and evaluated the ability of alpha1D-AR to cross-talk with TRPV1 in PCa cell lines.
Methods: The expression of alpha1D-AR and TRPV1 was examined in human PCa tissues by quantitative RT-PCR
and in PCa cell lines (DU145, PC3 and LNCaP) by cytofluorimetry. Moreover, alpha1D-AR and TRPV1 colocalization was
investigated by confocal microscopy in PCa cell lines and by fluorescence microscopy in benign prostate hyperplasia
(BPH) and PCa tissues. Cell proliferation was assessed by BrdU incorporation. Alpha1D-AR/TRPV1 knockdown was
obtained using siRNA transfection. Signalling pathways were evaluated by measurement of extracellular acidification
rate, Ca2+ flux, IP3 production, western blot and MTT assay.
Results: The levels of the alpha1D-AR and TRPV1 mRNAs are increased in PCa compared to BPH specimens and a
high correlation between alpha1D-AR and TRPV1 expression levels was found. Moreover, alpha1D-AR and TRPV1
are co-expressed in prostate cancer cell lines and specimens. Noradrenaline (NA) induced an alpha1D-AR- and
TRPV1-dependent protons release and Ca2+ flux in PC3 cell lines; NA by triggering the activation of phospholipase C
(PLC), protein kinase C (PKC) and extracellular signal-regulated kinase 1/2 (ERK1/2) pathways stimulated PC3 cell
proliferation, that was completely inhibited by clopenphendioxan (WS433) and capsazepine (CPZ) combination or
by alpha1D-AR/TRPV1 double knockdown.
Conclusions: We demonstrate a cross-talk between alpha1D-AR and TRPV1, that is involved in the control of PC3
cell proliferation. These data strongly support for a putative novel pharmacological approach in the treatment of
PCa by targeting both alpha1D-AR and TRPV1 channels.
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Calcium (Ca2+) signalling is essential for regulating
physiological functions such as cell proliferation and
differentiation [1]. Prostate cancer is the second most
lethal tumour among men, and Ca2+ has been shown to
be essential for increased cell proliferation in advanced
prostate cancer (PCa) cells [2-4]. However, the ion chan-
nel(s) involved in Ca2+ entry are not fully understood
and the mechanism that leads to alteration of Ca2+
handling in PCa is still poorly defined. Understanding
the factors that drive PCa towards increased cell prolif-
eration is crucial for the development of new therapies
that can prevent and/or inhibit the initiation and/or pro-
gression of PCa.
Among the transient receptor potential (TRP) channel
proteins, human TRP vanilloid type 1 (TRPV1) is expressed
in normal prostate epithelial cells, PCa tissues and in
PC3 as well as LNCaP cells [5]. The expression of
TRPV1 has been found to be significantly up-regulated
in PCa compared with benign prostate hyperplasia
(BPH) tissues, and the increased expression of TRPV1
correlates with increasing PCa tumour grade [6].
Alpha1-Adrenoceptors (α1-ARs) mediate actions of the
endogenous adrenaline and noradrenaline (NA) in several
target cells. On the basis of pharmacological and binding
studies α1-ARs have been subdivided into three subtypes,
namely α1A (α1a), α1B (α1b) and α1D (α1d) [7]. α1-AR
subtypes show different cellular localization: α1B-AR is
mainly expressed on cell surface [8,9], α1A-AR is
evidenced on the cell surface and intracellularly [10,11]
and α1D-AR appears to be localized primarily perinu-
clearly [8,9]. Moreover, α1-ARs are expressed in a
variety of human tissues, including liver, kidneys, blood
vessels, heart and prostate. In the human prostate α1A-AR
and α1B-AR subtypes are expressed in BHP [12,13], PCa
tissues as well as in PC3 and DU145 PCa cell lines [14,15]
whereas the α1D-AR subtype in the PC3 cell line [16,17].
The α1-ARs are G-protein-coupled receptors (GPCRs)
that are linked to the heterotrimeric G-protein containing
the Gαq/11/14/16 subunits. The Gαq subunit is a primary
activator of phospholipase C (PLC), which promotes the
cleavage of inositol 4,5-bisphosphate (PIP2) to yield diacyl-
glycerol (DAG) and inositol 1,4,5-triphosphate (IP3). DAG
and IP3 then promote the activation of protein kinase C
(PKC). Growing evidence supports the role for α1-ARs in
the direct mitogenic effect of catecholamines on prostate
growth [18]. We previously reported the expression of
the α1B- and α1D-AR subtypes in PC3 cells and the ability
of NA to stimulate PC3 cell proliferation in a α1D-AR-
dependent manner [17]. Therefore, the aim of the present
study was to evaluate the correlation between α1D-AR
and TRPV1 expression levels in patients with PCa and
to demonstrate the role of TRPV1 in the regulation of
NA-induced α1D-AR-dependent PC3 cell proliferation.Methods
Prostate cancer cell line
Human prostate cancer cell lines PC3, and DU145 were
purchased from American Type Culture Collection (ATCC,
Rockville, MD). Cell lines were maintained in DMEM
and RPMI medium (Lonza Group Ltd, Basel Switzerland),
respectively, supplemented with 10% heat-inactivated
fetal bovine serum (FBS, Lonza), 100 IU/ml of penicillin,
100 μg/ml of streptomycin at 37°C, 5% CO2 and 95% of
humidity. The androgen sensitive cell line LNCaP was
purchased from Istituto Zooprofilattico Sperimentale della
Lombardia e dell’Emilia Romagna (IZSLER, Brescia, Italy)
and maintained in RPMI supplemented as above described
at 37°C, 5% CO2 and 95% of humidity.
PCa tissues
Specimens (n = 37), from adult patients with high-risk
clinically localized adenocarcinoma of the prostate under-
went radical prostectomy at the Urology Operative Unit,
ASUR 9 Macerata, were collected for qRT-PCR analysis
(Additional file 1: Table S1). As control, 5 samples of BPH
tissues removed by transurethral resection were used. All
the specimens were embedded in paraffin and 5–7 μm-
thick sections were collected on slides. Patients, giving
their informed written consent, that covered the use
of their tissues for research purposes, were included in
the prostate cancer database of the Pathology Unit,
ASUR 9. The study was approved by the Ethics committee
Ospedale Civile Macerata and ASUR 9 and all procedures
were conducted in accordance with the Declaration of
Helsinki.
Antibodies and reagents
The following anti-human polyclonal antibodies (Abs)
were used: goat anti-TRPV1, rabbit anti-α1D-AR from
Santa Cruz Biotechnology (Heidelberg, Germany), rabbit
anti-ERK, rabbit anti-phospho p38 (anti-pp38), rabbit
anti-p(Ser)-PKC substrate and rabbit anti-p38 from Cell
Technology (Danvers, MA). The following anti-human
mouse monoclonal Abs (mAbs) were used: anti-GAPDH
(Sigma Aldrich, St. Louis, MO), anti-pERK (Cell) and
anti-Bromodeoxyuridine (BrdU) fluorescein isothiocyanate
(FITC)-conjugated (Prodotti Gianni, Italy). The horserad-
ish peroxidise (HRP)-conjugated donkey anti-goat and
donkey anti-mouse from Santa Cruz Biotechnology,
HRP-conjugated goat anti-rabbit Ab from Cell Signaling.
Purified FITC-conjugated rabbit anti-goat (RAG)IgG (EMD
Chemicals, Inc. San Diego, CA), phycoerythrin (PE)-conju-
gated goat anti-rabbit (GARB) IgG (BD Biosciences, San
Jose, CA), Alexa Fluor 488-conjugated rabbit anti-goat
and Alexa Fluor 594-conjugated goat anti-rabbit Abs
(Invitrogen, Carlsbad, CA) were used as secondary Abs.
{2-[2-(4-Chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethox
yphenoxy)ethyl]amine (clopenphendioxan, WS433, α1D-AR
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of Pharmacy, University of Camerino [17]. NA, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), BrdU and dimethyl sulfoxide (DMSO, used as
vehicle) from Sigma Aldrich. Chelerythrine chloride (PKC
inhibitor), U73122 (PLC inhibitor), PD98059 (MEK inhi-
bitor) and the TRPV1 antagonist, capsazepine (CPZ) [19]
were purchased from Tocris Bioscience (Bristol, UK).
Double immunofluorescence and flow cytometry
To determine the co-expression of TRPV1 and α1D-AR,
3×105 PC3, DU145 and LNCaP cells were fixed with 4%
paraformaldheyde in PBS for 10 min at room temperature,
washed with permeabilizing solution (1% FBS, 0.1%
saponin and 0.1% sodium azide in PBS) and stained for
30 min at 4°C first with anti-TRPV1 Ab (1:25) followed
by FITC-RAG (1:40) and then with anti-α1D-AR (1:25)
followed by PE-GARB (1:40). Normal goat and rabbit
serum were used as negative control. In some experi-
ments double immunofluorescence and FACS analysis
were performed in PC3 cells double silenced for α1D-AR
and TRPV1 genes. The percentage of positive cells de-
termined over 10,000 events was analyzed on a FACS-
can cytofluorimeter (BD Bioscience) and fluorescent
intensity was expressed in arbitrary units on a logarith-
mic scale.
Confocal laser scanning microscopy analysis
2 × 105/mL PC3 cells grown for 24 h at 37°C in poly-L-
lysine coated slides, were permeabilized using 2% of
paraformaldehyde with 0.5% of Triton X-100 in PBS and
fixed by 4% of paraformaldehyde in PBS. After washes in
PBS, cells were incubated with 3% of bovine serum albu-
min (BSA) and 0.1% of Tween-20 in PBS for 1 h at room
temperature and then double stained with anti-TRPV1
(1:25) and anti-α1D-AR (1:25) Abs overnight at 4°C.
Finally, samples were washed with 0.3% of Triton X-100
in PBS, incubated with Alexa Fluor 488-conjugated and
Alexa Fluor 594-conjugated secondary Abs (1:100) for
1 h at 37°C and analysed with MRC600 confocal laser
scanning microscope (BioRad, Hercules, CA) equipped
with a Nikon (Diaphot-TMD) inverted microscope. Fluoro-
chrome was excited with the 600 line of an argon-kripton
laser. Serial optical sections were taken at 1-μm intervals
through the cells. Images were processed using Jacs Paint
Shop Pro (Jacs Sotfware Inc).
Fluorescence microscopy analysis
The co-expression of α1D-AR and TRPV1 in tissue spec-
imens from patients with adenocarcinoma or BHP, used
as control, was evaluated by double immunofluores-
cence. Briefly fixed paraffin-embedded tissue slices were
deparaffinized, rehydrated and washed with 0.3% Triton
X-100 in PBS. After incubation with 3% of BSA and 0.3%of Triton X-100 in PBS for 1 h at room temperature,
sections were first stained with anti-α1D-AR (1:25) Ab
overnight at 4°C, washed with 0.3% of Triton X-100 in
PBS and then labelled with Alexa Fluor 594-conjugated
secondary Ab (1:100) for 1 h at 37°C. Subsequently,
samples were washed with 0.3% of Triton X-100 in PBS
and incubated with anti-TRPV1 (1:25) overnight at 4°C
followed by Alexa Fluor 488-conjugated Ab (1:100) for
1 h at 37°C. Sections were analyzed using a BX51 fluor-
escence microscope at 10× magnification (Olympus,
Milan, Italy). Merge images were obtained by using the
DP controller software (Olympus).
Western blot analysis
PC3 cells were lysed in lysis buffer (10 mM Tris, pH 7.4,
100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF,
20 mM Na4P2O7, 2 mM Na3VO4, 1% Triton X-100, 10%
glycerol, 0.1% SDS, 0.5% deoxycholate, 1 mM phenyl-
methylsulfonylfluoride) containing protease inhibitor
cocktail (SigmaAldrich) by using the Mixer Mill MM300
(Qiagen GmbH, Hilden, Germany). Lysates from PC3
cells treated for different times with NA (100 μM),
WS433 (1 μM) and CPZ (1 μM) alone or in combin-
ation, were separated on 8 and 12% SDS-polyacrylamide
gels, transferred and blotted with anti-pERK (1:1000)
mAb followed by HRP-conjugated anti-mouse (1:1000) Ab,
anti-ERK (1:1000), anti-p(Ser)-PKC substrate (1:1000),
anti-pp38 (1:2000) and anti-p38 (1:2000) Abs followed
by HRP-conjugated anti-rabbit (1:2000) Ab. Anti-GAPDH
mAb was used as protein loading control. To verify silen-
cing efficiency, lysates from siTRPV1 or siα1D-AR PC3 cells
were immunoblotted with anti-TRPV1 (1:100) or anti-α1D-
AR (1:1000) Abs followed by HRP-conjugated anti-goat
(1:1000) and anti-rabbit (1:2000) Abs respectively. Immu-
noreactivity was detected using the LiteAblot ®PLUS (Euro-
Clone, Milan, Italy) kits and densitometric analysis was
carried out by evaluating three independent experiments
by a Chemidoc using the Quantity One software (BioRad,
Hèrcules, CA).
Measurement of extracellular acidification rate (ECAR)
The eight-channel CytosensorTM microphysiometer
(Molecular Devices Corp., Sunnyvale, CA, USA) was
used as previously described [20] to evaluate small
changes in the extracellular release of protons induced
by NA in the culture medium surrounding PC3 cells.
Briefly, 3 × 105 PC3 cells were seeded into 12-mm
capsule cups and cultured for 24 h. Then the capsule
cups were loaded into the sensor chambers and the
chambers were perfused with running medium (bicar-
bonate-free DMEM with 0.584 g/L glutamine and
2.59 g/L NaCl) at a flow rate of 100 μL /min. PC3 cells
were stimulated for 30 sec with vehicle, NA (100 μM),
WS433 (1 μM), CPZ (1 μM), alone or in combination,
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either fluid path. ECAR rate data were expressed as
percentages of response respect to the baseline value.Gene silencing
siGENOME SMARTpools for TRPV1 (siTRPV1) and for
α1D-AR (siα1D-AR) consisting of four RNA duplex tar-
geting respectively TRPV1 and α1D-AR genes, and a
siCONTROL non-targeting small interfering RNA (siGLO)
with at least four mismatches to any human gene used as
negative control were purchased from Dharmacon (Lafayette,
CO). Briefly, 4×104/ml PC3 cells were plated and after
an overnight incubation, 20 nM of siTRPV1, siα1D-AR or
siGLO was added to the wells, following METAFECTENE
SI (Biontex Laboratories GmbH, Martinsried/Planegg,
Germany) transfection protocol. Cells were harvested at
day 2 post-transfection for analysis.Total RNA extraction and complementary DNA synthesis
Total RNA from siGLO, siTRPV1 and siα1D-AR PC3 cells
was extracted with the RNeasy Mini Kit (Qiagen GmbH,
Hilden, Germany). Total RNA from fixed paraffin-
embedded tissue slices (5–7 μm-thick) was isolated by
Absolutely RNA® formalin-fixed, paraffin-embedded (FFPE)
kit (Stratagene, Austin, TX, USA). Five hundred ng of
extracted RNA were subjected to reverse transcription
using the High-Capacity cDNA Archive Kit (Life Tech-
nologies Corporation, Carlsbad, CA). One μL of the
resulting cDNA products was used as template for qRT-
PCR quantification.qRT-PCR analysis
qRT-PCR was performed using the iQ5 Multicolor Real-
Time PCR Detection System (Bio-Rad). The reaction mix-
ture contained the Syber Green Master Mix (Bio-Rad) and
primer sets. Human β-actin, TRPV1 and α1D-AR primers
designed with Primer Premier 5 (Bio-Rad, Hèrcules, CA)
and purchased from SigmaAldrich. Primers sequences
were: β-actin: forward 5′-ATCAGCAAGCAGGAGTAT
GACG -3′; reverse 5′-AAAGCCATGCCAATCTCATC
TG-3′; TRPV1: forward 5′ -CTGATGGCAAGGACGA
CTACC-3′; reverse: 5′ -TTGACCGCAGGGAGAAGC
TC-3′; α1D-AR: forward 5′ -GGTCGTAGCCCTGGTG
GTG -3′; reverse: 5′ -CGGAGGAGAAGACAGCGTAGC
-3′. Each amplification consisted of heat activation for
15 min at 95°C followed by 40 cycles at 95°C for 10 sec
and 60°C for 50 sec. All samples were assayed in tripli-
cate in the same plate and in three different expe-
riments. Measurement of β-actin levels was used to
normalize mRNA contents. TRPV1 and α1D-AR levels
were calculated by the 2-ΔΔCt method and expressed as
relative fold respect to control levels.[Ca2+]i measurement
3×106/mL PC3 cells were washed in calcium and mag-
nesium free PBS supplemented with 4.5 g/L of glucose
used as experimental medium. Cells were resuspended
in the medium supplemented with 7 μmol/L FLUO
3-AM and 1 μg/mL Pluronic F-127 (Life Technologies
Corporation, Carlsbad, CA) and incubated in the dark for
30 min at 37°C, 5% CO2. After washing, cells were resus-
pended in the medium containing or not 2 mmol/L Ca2+
and stimulated with vehicle, NA (100 μM), WS433 (1 μM),
CPZ (1 μM), alone or in combination. Fluorescence was
measured by FACScan; not stimulated cells were analyzed
for 2 min to establish baseline fluorescence levels.Proliferation assay
BrdU incorporation was determined in PC3 cells
treated for 24 h with NA (100 μM), WS433 (1 μM) and
CPZ (1 μM), alone or in combination and in siGLO,
siTRPV1 and siα1D-AR PC3 cells treated with NA
(100 μM) for 24 h. Cells were labelled by adding 20 μL/
well of BrdU. After trypsinization and washing in PBS
supplemented with 0.5% BSA and 2 mM ethylenedi-
aminetetraacetic acid, cells were fixed for 30 min in
PBS containing 30% methanol and 0.4% paraformald-
heyde, permealized with PBS containing 1% parafor-
maldheide and 0.01% Tween-20, and then incubated
for 15 min in DNAse buffer containing 500 KU/mL of
DNAse (SigmaAldrich). Thereafter, cells were stained
with anti-BrdU FITC-conjugated Ab (1:10) incubated
for l h at room temperature and washed in PBS con-
taining 0.5% BSA and 2 mM ethylenediaminetetraacetic
acid. Samples were analyzed by a FACScan cytofluori-
meter as above described.MTT assay
Cell growth was measured by MTT assay. 4 × 104 PC3
cells/mL were plated in a 96-well microtiter plate,
treated for 24 h with NA (100 μM), WS433 (1 μM) and
CPZ (1 μM), alone or in combination and then incu-
bated with 0.8 mg/ml of MTT for the last 3 h. Four
replicates were used for each treatment. The superna-
tants were discarded and colored formazan crystals,
dissolved with 100 μL/well of DMSO, were read at
570 nm wavelength by an ELISA reader (BioTek
Instruments, Bad Friedrichshall, Germany). In some
experiments, MTT assay was performed in PC3 cells
treated for 24 h with NA (100 μM), chelerythrine
(0.5 μM), U73122 (5 μM) and PD98059 (50 μM), alone
or in combination. Dose response curves have been
performed after 24 h treatments for chelerythrine,
U73122 and PD98059 compounds (Additional file 2:
Figure S1F). The highest doses that did not affect cell
viability were used.
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IP3 was measured using the inositol-1,4,5-trisphosphate
[3H] radioreceptor assay kit (PerkinElmer Life Sciences,
Inc., Waltham, MA) [21]. Briefly, 1.5×105/mL PC3 cells
were treated with NA (100 μM), WS433 (1 μM) and
CPZ (1 μM), alone or in combination for different times
in DMEM supplemented with 1% FBS. After treatment
IP3 was read by β scintillation counter in 5 ml of Atom-
light scintillation cocktail (PerkinElmer).
Statistical analysis
The statistical significance was determined by one-way
Anova or by 2-way Anova with Bonferroni post-test. Un-
paired t tests and Spearman’s rank correlation tests were
performed with GraphPad Prism version 5.0 (GraphPad
Software, San Diego, CA, USA). No differences were
found comparing vehicle-treated with untreated PC3
cells (control).
Results
α1D-AR and TRPV1 are co-expressed in the prostate cancer
cell lines
Previously reports have evidenced the expression of the
vanilloid receptor, TRPV1 [6] and the α1D-AR [17] in the
PC3 cell line; however, data on correlation between these
receptors in PCa has not been provided so far. Therefore,
by double immunofluorescence and flow cytometric ana-
lysis, we found that the α1D-AR and TRPV1 proteins were
co-expressed in the androgens-resistant PC3 and DU145
cell lines, although at different levels. ApproximatelyFigure 1 α1D-AR and TRPV1 are co-expressed and co-localized in pros
and LNCaP cells double-stained with anti-TRPV1 and anti-α1D-AR Abs follow
performed using PC3 cells grown for 24 h on poly-L-lysine coated slides, p
followed by Alexa Fluor 488- and Alexa Fluor 594-conjugated secondary Ab
of three separate experiments.78.9% and 64.3% of PC3 cells and 71.6% and 58.1% of
DU145 expressed TRPV1 and α1D-AR, respectively,
with 52.4% and 40.7% of them co-expressing both
receptors (Figure 1A). In addition double immuno-
fluorescence, performed in the androgens sensitive
cell line LNCaP, showed that about 66.9% and 50.3% of
this cell line expressed TRPV1 and α1D-AR, with 39.6%
co-expressing both receptors, suggesting that the
co-expression of α1D-AR and TRPV1 does not depend
on the androgen sensitivity. Moreover, by confocal
microscopy, we observed the co-localization of α1D-AR
and TRPV1 primarily in the plasma membrane and in
intracellular perinuclear vesicles of PC3 cells (Figure 1C).
Co-expression of α1D-AR and TRPV1 in PCa tissues
The results obtained in prostate cancer cell lines were
confirmed at mRNA levels in PCa specimens. Thus, we
assessed the expression of α1D-AR mRNA in tissues
from prostatectomised patients (n = 37) with advanced
PCa (Additional file 1: Table S1). Using quantitative
RT-PCR (qRT-PCR), we found that α1D-AR was over-
expressed (2.44 ± 0.20) in PCa compared with BPHs
(1.0 ± 0.05) (Figure 2A). As previously reported [6], we
observed that TRPV1 mRNA expression significantly
increased in PCa tissues (1.84 ± 0.12) compared with BPH
tissues (0.61 ± 0.01) (Figure 2B); interestingly we found
that TRPV1 levels highly correlated with α1D-AR expres-
sion (correlation index: r = 0.88; p < 0.0001) (Figure 2C).
Dramatic reduction in the α1D-AR and TRPV1 mRNA
levels was observed in PCa specimens (n = 5, pathologicaltate cancer cells. (A) FACS analysis was performed in PC3, DU145
ed by respective secondary Abs. (B) Confocal microscopy analysis was
ermeabilized and double-stained with anti-TRPV1 and anti-α1D-AR Abs,
s, respectively. Bar: 20 μm. Data shown are representative of one out
Figure 2 Co-expression of α1D-AR and TRPV1 in PCa specimens. (A-B) Fold expression levels of α1D-AR and TRPV1 in PCa and BPH specimens
analysed by qRT-PCR. Each point represents the expression level in a single subject. (C) Correlation between the α1D-AR and TRPV1 expression levels.
Spearman’s rank correlation coefficient (r) is indicated in the graph. (D-E) Fold expression levels of α1D-AR and TRPV1 in PCa and bicalutamide-treated
PCa specimens analysed by qRT-PCR. Each point represents the expression level in a single subject. The horizontal bars within the plots indicate the
median percentage for each group. Significant differences between groups were identified by unpaired t tests and are indicated above the groups:
*p < 0.0001. (F) Fluorescence microscopy analysis was performed in PCa and BHP tissues double-stained with anti-TRPV1 and anti-α1D-AR Abs,
followed by Alexa Fluor 488- and Alexa Fluor 594-conjugated secondary Abs, respectively. Magnification: 10×. Data shown are representative of
one out of three separate experiments.
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vant androgen deprivation therapy compared with tissues
from untreated PCa patients (Figure 2D and E). Moreover,
by using double immunofluorescence and fluorescence
microscopy analysis, we also showed that α1D-AR and
TRPV1 proteins are co-expressed in PCa tissues and thattheir expression is increased in PCa compared with BPH
tissues (Figure 2F).
The cross-talk between α1D-AR and TRPV1 receptors
The ability of NA to sensitise TRPV1 was studied in PC3
cells. First, we used a CytosensorTM microphysiometer to
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(100 μM) with or without α1D-AR antagonist, WS433,
(1 μM) and TRPV1 antagonists, CPZ (1 μM). We found
that protons release following NA administration, was
not only α1D-AR- but also TRPV1-dependent as shown
by the inhibitory effects induced by both WS433 (60%)
and CPZ (35%). In addition, the combination of WS433
and CPZ completely inhibited the NA-induced acid
activation (Figure 3A). No activation was found when
using WS433 and CPZ alone respect to control PC3
cells (Additional file 2: Figure S1A). Thereafter, we
followed NA-induced Ca2+ flux by FACS analysis in
PC3 cells loaded with Fluo-3 AM. NA stimulation in
Ca2+-containing PBS/glucose medium induced a rapid
response that peaked at 40 sec after treatment with an
increase in [Ca2+]i from 300 to 650 nM (Figure 3B).
Next, we addressed the contribution of both α1D-AR
and TRPV1 components by using WS433 and CPZ.
Complete abrogation of the NA-induced increase in
[Ca2+]i was observed with all the antagonists (Figure 3B).Figure 3 The α1D-AR and TRPV1 cross-talk in PC3 cells. (A) The measur
Cytosensor TM microphysiometer was performed with PC3 cells stimulated fo
with WS433 (1 μM) or/and CPZ (1 μM). Data shown are the mean ± SD of thre
NA-treated cells with control cells (*) and NA+WS433-, NA + CPZ- and NA +W
[Ca2+]i increase in Fluo-3-loaded PC3 cells vehicle-treated (control) or treated w
by FACS analysis. Data shown are the mean ± SD of three separate experimen
control cells (*) and NA+WS433-, NA + CPZ- and NA+WS433 + CPZ- with NANo Ca2+ flux was found when using WS433 and CPZ
alone respect to control PC3 cells (Additional file 2:
Figure S1B).
The α1D-AR/TRPV1 cross-talk in response to NA activates
specific signalling pathways
Several reports have examined the role of the PLC-PKC-
MAPK signalling pathways in the catecholamine-
induced α1D-AR-mediated proliferation of prostate
cancer cells [22,23]. Thus, we studied the effect of α1D-
AR and TRPV1 cross-talk in the NA-induced activation
of PLC, PKC and ERK signalling pathways. Time-course
analysis of NA-induced PLC activation, evaluated as IP3
production, evidenced that NA stimulates IP3 produc-
tion 5 min after NA treatment, remaining sustained at
30 min and declining thereafter (Figure 4A). Moreover, we
found that ERK1/2 is phosphorylated at basal level and
NA induces a rapid and transient increase of its phosphor-
ylation at 3 min after treatment (Figure 4B); NA also
increased the (Ser)-PKC substrate phosphorylation atement of the extracellular acidification rate using an eight-channel
r 30 sec with vehicle (control) or NA (100 μM) alone or in combination
e separate experiments. Statistical analysis was performed by comparing
S433 + CPZ- with NA-treated cells (**), p≤ 0.01. (B) The time course of
ith NA alone or in combination with WS433 or/and CPZ was evaluated
ts. Statistical analysis was performed by comparing NA-treated cells with
-treated cells (**), p≤ 0.01.
Figure 4 NA induces PLC, PKC and ERK activation in PC3 cells. (A) The measurement of IP3 levels using the IP3 [
3H] Radioreceptor assay kit was
performed in PC3 cells vehicle-treated (control) or treated for different times with NA (100 μM). Data shown are the mean ± SD of three separate
experiments. Statistical analysis was performed by comparing NA-treated with control cells, *p≤ 0.01. (B-C) Lysates from PC3 cells vehicle-treated
(control) or treated for different times with NA (100 μM) were separated on SDS-polyacrylamide gels, transferred and then blotted with anti-pERK,
anti-ERK, anti-p38, anti-pp38 and anti-phospho-(Ser) PKC substrate Abs. The GAPDH protein level was evaluated as a loading control. Data shown are
representative of one out of three separate experiments. Densitometric analysis was performed evaluating three different experiments and statistical
analysis was carried out comparing NA-treated with control cells, *p≤ 0.01.
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http://www.biomedcentral.com/1471-2407/14/9213–5 min and then return to basal level (Figure 4C); p38
was basally phosphorylated, and NA stimulation did
not affect its phosphorylation state (Figure 4B).
Then the ability of WS433 or CPZ to inhibit PLC acti-
vation, ERK1/2 phosphorylation and the production of
phospho-(Ser) PKC substrates was assessed. In regard to
PLC activation, when used in combination with NA
CPZ, but not WS433, partially inhibited IP3 production;
however, NA administered in combination with WS433and CPZ induced a IP3 production, but at a lower rate than
NA in combination with CPZ (Figure 5A). No IP3 produc-
tion was found when using WS433 and CPZ alone respect
to control PC3 cells (Additional file 2: Figure S1C). The
NA-induced ERK1/2 phosphorylation was markedly
affected by both the α1D-AR and TRPV1 antagonists or by
their combination (Figure 5B), whereas the NA-induced
increase of (Ser)-PKC substrate phosphorylation was
reduced only by CPZ and WS433 used in combination
Figure 5 Role of TRPV1 and α1D-AR in NA-induced PLC, PKC and ERK activation. (A) The IP3 levels, measured as above described, were
evaluated in PC3 cells treated for 5 min with NA (100 μM), either alone or in combination with CPZ (1 μM), WS433 (1 μM) or CPZ +WS433. Data
shown are the mean ± SD of three separate experiments. Statistical analysis was performed by comparing NA +WS433-, NA + CPZ- or NA + CPZ +
WS433- with NA-treated cells, *p≤ 0.01. (B-C) Lysates from PC3 cells vehicle-treated (control) or treated for 3 min with NA (100 μM) alone or in
combination with WS433 (1 μM) and/or CPZ (1 μM), were separated on SDS-polyacrylamide gels, transferred and then blotted with anti-pERK, ERK
and anti-phospho-(Ser) PKC substrate Abs. The GAPDH protein level was evaluated as a loading control. Data shown are representative of one out of
three separate experiments. Densitometric analysis was performed evaluating three different experiments and statistical analysis was performed
by comparing NA-treated cells with control cells (*) and NA +WS433-, NA + CPZ- and NA +WS433 + CPZ- with NA-treated cells (**), p ≤ 0.01.
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http://www.biomedcentral.com/1471-2407/14/921(Figure 5C). No ERK1/2 and (Ser)-PKC substrate phos-
phorilation was found when using WS433 and CPZ
alone respect to control PC3 cells (Additional file 2:
Figure S1D, E). Next, the ability of pharmacological
inhibitors of PLC, PKC and ERK to inhibit the NA-
induced PC3 cell growth was evaluated. We found that
U73122, chelerythrine chloride and PD98059, used at the
highest doses that did not affect cell viability (Additional
file 2: Figure S1F), markedly inhibited the cell growth of
NA-stimulated PC3 cells; in addition, when all the three
pharmacological inhibitors were used in combination, theycompletely reverted the NA-mediated effects (Figure 6).
These results confirmed that the PLC/PKC/ERK axis plays
a major role in the control of α1D-AR- and TRPV1-
dependent PC3 cell growth.
NA stimulates the proliferation of PC3 cells in a α1D-AR- and
TRPV1-dependent manner
We previously reported the role of α1D-AR in the NA-
induced proliferation of PC3 cells [17]. Thus, we evaluated
the potential contribution of TRPV1 to the NA-induced
α1D-AR-mediated proliferation of PC3 cells. We found that
Figure 6 PLC, PKC and MAPK inhibitors block the NA-induced
PC3 cell survival. Cell growth was assessed by MTT assay in PC3 cells
treated for 24 h with vehicle (control) or NA (100 μM), alone or in
combination with chelerythrine (0.5 μM), U73122 (5 μM) and PD98059
(50 μM). Data shown are the mean ± SD of three separate experiments.
Statistical analysis was performed by comparing NA-treated with
control cells (*), NA + chelerythrine-, NA + PD98059-, NA + U73122- and
NA + chelerythrine + PD98059 + U73122- with NA-treated cells (#) and
NA + chelerythrine + PD98059 + U73122- with NA+ chelerythrine-,
NA + PD98059- and NA+U73122-treated cells (§), p≤ 0.01.
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liferation. No change in proliferation rate was observed
when using WS433 and CPZ alone respect to control PC3
cells (Additional file 2: Figure S1G). Then, to strengthen
these findings, we performed cell proliferation in single
(α1D-AR or TRPV1) and double (α1D-AR/TRPV1) silenced
PC3 cells (Additional file 3: Figure S2A, B, C). A marked
decrease in NA-induced proliferation was already evident
in siα1D-AR and siTRPV1 cells even if a stronger inhib-
ition (< 80%) was observed in double siα1D-AR/siTRPV1
PC3 cells (Figure 7B).
Discussion
TRP channels may participate in Ca2+ homeostasis in
PCa cells [24]. It has been hypothesised that abnormal Ca2+
signalling may be an essential step in the α1-AR-mediated
increased proliferation in PCa cells [3].
Herein, we firstly demonstrated that prostate cancer cell
lines co-expressed α1D-AR and TRPV1 proteins and these
receptors co-localized mainly in the plasma membrane,
perinuclear region and intracellular vesicles. Therefore, we
investigated whether these receptors functionally interact
each other. Previously, cross-sensitisation between TRPV1
and other members of the GPCR family, such as P2X3
and CCR1 in DRG neurons [25] and CCR1/TRPV1-trans-
fected human embryonic kidney (HEK293) cells, respect-
ively, have been demonstrated [26].
We also evaluated the α1D-AR and TRPV1 co-expression
at mRNA and protein levels in advanced PCa tissues. Aspreviously reported [6], TRPV1 mRNA expression is higher
in PCa than in BPH tissues. Our data demonstrated that
α1D-AR mRNA and protein levels were markedly increased
in PCa samples compared with BPH specimens and,
more importantly, that there is a great correlation
between α1D-AR and TRPV1 expression levels. Moreover,
a strong reduction of the α1D-AR and TRPV1 mRNAs was
observed in 5/37 PCa patients who received neoadjuvant
androgen deprivation therapy compared with untreated
PCa patients. This result suggests that the transcrip-
tional activity of TRPV1 and α1D-AR may be androgen
dependent. Chromatin immunoprecipitation analysis
revealed that TRPV1 is a novel androgen receptor target
gene in castration-resistant C4-2 PCa cells [27]. Similarly,
decreased TRPV6 levels were detected in androgen-
insensitive tumours after androgen deprivation therapy
[2]. No data on the relationship between α1D-AR and
androgen receptors has been published to date; however,
the expression of β2-AR, a well-known activator of the
androgen receptors, was transiently down-regulated in
hormone-sensitive LNCaP cells treated with the anti-
androgen compound bicalutamide [28,29]. Thus, there
may be a similar effect on α1D-AR in PCa patients treated
with anti-androgen drugs.
α1D-AR has a 10- to 100-fold higher affinity for en-
dogenous catecholamines than the α1A- and α1B-AR
subtypes [30]. Therefore, we studied whether the bind-
ing of NA to α1D-AR sensitises TRPV1 in PC3 cells. By
protons release and Ca2+ flux analysis NA resulted in a
rapid response, which was inhibited by WS433 and
CPZ. Moreover, NA stimulates a cross-talk between α1D-
AR and TRPV1 in PC3 cells that involves the PLC-PKC-
ERK pathways. In particular, NA sensitises TRPV1, but
not α1D-AR, to activate the PLC pathway. This result is in
agreement with previous findings demonstrating a weaker
coupling between PLC and α1D-AR than between PLC
and other α1-AR subtypes [9,31]. Calcium flowing through
TRPV1 activates PLC, and the resulting depletion of PIP2
plays a role in PKC-dependent TRPV1 sensitisation [32].
Moreover, recently TRPV1 has been demonstrated to be
either inhibited or activated by PIP2 [33]. In this regard,
we found that the IP3 production is a TRPV1-dependent
event; WS433 in combination with CPZ significantly
inhibited the IP3 production to a greater extent than
CPZ alone, suggesting a co-stimulatory effect of α1D-AR
signalling in sustained TRPV1-dependent PLC activa-
tion. Moreover, the CPZ and WS433 drug combination
significantly reduced the NA-induced phospho-(Ser)
PKC substrate phosphorylation. Finally, both CPZ and
WS433 antagonists alone markedly inhibited the ERK1/2
phosphorylation, although the maximal effect was evi-
denced by their use in combination, suggesting that
ERK1/2 represents a downstream component of NA-
induced TRPV1 and α1D-AR signalling pathway. In this
Figure 7 NA stimulates the proliferation of PC3 cells in an α1D-AR and TRPV1 dependent manner. (A) The proliferation of PC3 cells was
analysed by labelling with BrdU. The cells were treated with vehicle (control) or NA (100 μM) for 24 h, alone or in combination with WS433 (1 μM) and
CPZ (1 μM). Cells were stained with an anti-BrdU FITC-conjugated Ab and analysed using a FACScan flow cytometer. Data shown are representative of
one of three separate experiments. (B) siGLO-, siα1D-AR-, siTRPV1- and siα1D-AR/siTRPV1-transfected PC3 cells were treated for 24 h with NA (100 μM),
and cell proliferation was assessed by BrdU labelling. The percentage increase of cell proliferation was evaluated with respect to vehicle-treated
cells. The data shown are the mean ± SD of three separate experiments. Statistical analysis was performed by comparing siα1D-AR-, siTRPV1- with
siGLO-transfected cells (*), and siα1D-AR/siTRPV1- with siα1D-AR- or siTRPV1-transfected cells (**), p ≤ 0.01.
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α1D-AR, a constitutive ERK1/2 phosphorylation, which
was reduced by incubation with the selective α1D-AR an-
tagonist BMY7378, was evidenced; in addition a rapid and
transient ERK1/2 phosphorylation, that was not inhibited
by the PKC inhibitor, Ro-8425, following α1D-AR activa-
tion was demonstrated [34]. Moreover, α1D-AR activation
stimulated the ERK pathway in CHO cells [35] and in
lacrimal gland epithelial cells [36].
Previous reports have indicated the contribute of α1D-AR
in NA-induced proliferation of PC3 cells [17], however
no data on the potential effects of TRPV channels in
PCa proliferation were reported. Herein we found that
complete abrogation of NA-induced increase in PC3
cell proliferation was reached only in double-silenced
α1D-AR/TRPV1 PC3 cells. The silencing of the α1D-AR
or TRPV1 gene or the use of WS433 or CPZ alone, par-
tially but not completely, inhibited the NA-induced
effects suggesting that these receptors act cooperatively.Coupling of α1-AR to Ca
2+-permeable TRPCs channels
has been reported in LNCaP cells [24,37,38] and WB4101
and the TRP channel blockers 2-ABP and SK&F 96365
[24]. Furthermore, naftopidil, an α1D-AR selective antag-
onist, has been also reported to affect the proliferation of
human prostate epithelial cells [39], and labedipinedilol-A,
which shows high selectivity for α1A- and α1D-AR, to
inhibit the NA-stimulated proliferation and ERK phos-
phorylation in LNCaP and PC3 cells [40]. Thus, because
of the lack of potent and selective subtype-specific α1-AR
antagonists, experimental or clinical trials using these
compounds are few [41,42].
Conclusion
Overall, our findings, demonstrating a functional co-
operative role played by the α1D-AR/TRPV1 cross-talk
in NA-induced proliferation of PCa cells, strongly sup-
port for a new pharmacological approach in the care of
PCa by targeting both the α1D-AR and TRPV1 receptors.
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Additional file 1: Table S1. Patient demographics. IQR = interquartile
range; PSA = prostate-specific antigen.
Additional file 2: Figure S1. Effects of WS433 and CPZ antagonists and
chelerythrine, PD98059, U73122 inhibitors in PC3 cells. (A) The measurement
of the extracellular acidification rate was performed as above described with
PC3 cells treated for 30 sec with vehicle (control) or WS433 (1 μM) or/and
CPZ (1 μM). Data shown are the mean ± SD of three separate experiments.
(B) The time course of [Ca2+]i increase in Fluo-3-loaded PC3 cells
vehicle-treated (control) or treated with WS433 or/and CPZ was
evaluated by FACS analysis. Data shown are the mean ± SD of three separate
experiments. (C) The measurement of IP3 levels performed as above described
in PC3 cells vehicle-treated (control) or treated for different times with WS433
(1 μM) or/and CPZ (1 μM). Data shown are the mean ± SD of three separate
experiments. (D-E) Lysates from PC3 cells vehicle-treated (control) or treated
for different times with WS433 (1 μM) or/and CPZ (1 μM) were separated on
SDS-polyacrylamide gels, transferred and then blotted with anti-pERK, ERK and
anti-phospho-(Ser) PKC substrate Abs. The GAPDH protein level was evaluated
as a loading control. Data shown are representative of one out of three
separate experiments. (F) Cell growth was assessed by MTT assay in PC3
cells treated for 24 h with vehicle (control) or with chelerythrine (0.05-5 μM),
PD98059 (1–100 μM) and U73122 (0.5-50 μM). Data shown are the mean ±
SD of three separate experiments. Statistical analysis was performed by
comparing chelerythrine, PD98059 and U73122 treated cells with control (*),
p≤ 0.01. (G) The proliferation of PC3 cells was analysed by labelling with
BrdU. The cells treated with WS433 (1 μM) or CPZ (1 μM) were stained
with an anti-BrdU FITC-conjugated Ab and analysed using a FACScan
flow cytometer. Data shown are representative of one of three separate
experiments.
Additional file 3: Figure S2. Silencing of the α1D-AR and TRPV1 genes
in PC3 cells. (A) The α1D-AR and TRPV1 mRNA levels were evaluated by
qRT-PCR in siGLO-, siα1D-AR- and siTRPV1-transfected PC3 cells. The relative
α1D-AR and TRPV1 expression levels, normalised to the β-actin mRNA level,
were calculated using siGLO as a calibrator. (B) Lysates from siGLO-, siα1D-AR-
and siTRPV1-transfected PC3 cells were separated by SDS-polyacrylamide gel
electrophoresis and probed with anti-α1D-AR or anti-TRPV1 Abs. The GAPDH
protein level was evaluated as a loading control. Representative immunoblots
are shown. (C) FACS analysis was performed in PC3 cells double silenced for
α1D-AR and TRPV1 genes. Silenced cells were double-stained with anti-TRPV1
and anti-α1D-AR Abs followed by respective secondary Abs. Data shown are
representative of one of three separate experiments.
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